The main treatments for ROP—laser photocoagulation and intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) agents—focus on the proliferative phase of the disease, which leads to neovascularization rather than the initial phase [15,16]. Here, VEGFA is linked to retinopathy of prematurity.